RxDoctor Payments Data

Lisa Burch, MD

Internal Medicine · Mobile, ALNPI 1932107943

Payments from drug & device makers

$8,916in general payments, 2019–2025

Across 625 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AstraZeneca$725
  • Pfizer$717
  • AbbVie$663
  • Novartis$641
  • Novo Nordisk$610
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,87199%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,916 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$157,214
Medicare patients
252
Services billed
5,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$245,510
FarxigaDapagliflozin Propanediol239$171,074
JanuviaSitagliptin Phosphate175$154,942
EliquisApixaban124$123,673
MounjaroTirzepatide104$119,669
JardianceEmpagliflozin94$59,521
LinzessLinaclotide53$53,971
XareltoRivaroxaban56$43,436
MyrbetriqMirabegron42$38,199
Bydureon BciseExenatide Microspheres21$20,366
EntrestoSacubitril/Valsartan22$13,931
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$12,242
RybelsusSemaglutide11$10,410
Atorvastatin Calcium719$9,137
KerendiaFinerenone12$8,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$610$255,921248 claims
AstraZenecaFarxiga$725$171,074239 claims
MerckJanuvia$483$154,942175 claims
PfizerEliquis$717$123,673124 claims
Lilly USA, LLCMounjaro$574$119,669104 claims
Boehringer IngelheimJardiance$146$59,52194 claims
AbbVieLinzess, Synthroid$663$57,01787 claims
Johnson & JohnsonXarelto$1,258$43,43656 claims
Astellas Pharma US IncMyrbetriq$186$38,19942 claims
NovartisEntresto$641$13,93122 claims
BayerKerendia$368$8,98412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →